The Human Antimicrobial Peptide LL-37 Suppresses Apoptosis in Keratinocytes  by Chamorro, Clara I. et al.
The Human Antimicrobial Peptide LL-37 Suppresses
Apoptosis in Keratinocytes
Clara I. Chamorro1, Gu¨nther Weber2, Alvar Gro¨nberg3, Andor Pivarcsi1 and Mona Sta˚hle1
The human cathelicidin antimicrobial peptide LL-37 is involved in various aspects of skin biology, including
protection against infection, wound healing, and also in psoriasis. The tight regulation of apoptosis is critical in
tissue repair and its deregulation is a part of the psoriasis phenotype. Despite being involved in cell death of
several cell types, virtually nothing is known about the function of LL-37 in keratinocyte apoptosis. Here we
report that LL-37 peptide protects primary human keratinocytes and HaCaT cells from apoptosis induced by the
topoisomerase I inhibitor camptothecin (CAM). In particular, pretreatment with LL-37 significantly decreased
caspase-3 activity after CAM-treatment. Expression profiling of keratinocytes treated with LL-37 identified the
upregulation of cyclooxygenase-2 (COX-2) expression, a gene implicated in protection from apoptosis. In
addition to inducing COX-2 expression, LL-37 stimulated the production of its product, prostaglandin E-2 (PGE-
2). Moreover, LL-37 induced the expression of inhibitor of apoptosis-2 (IAP-2), implicated in the COX-2/PGE-2
antiapoptotic pathway. Pretreatment with a selective COX-2 inhibitor abolished the antiapoptotic effect of LL-37
and reduced IAP-2 expression implicating that the antiapoptotic effect of LL-37 in keratinocytes is mediated by a
COX-2-dependent mechanism involving IAP-2. Thus, overexpression of LL-37 may contribute to reduced
keratinocyte apoptosis in conditions such as psoriasis.
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INTRODUCTION
Cathelicidins are a family of antimicrobial proteins found in
most mammalian species. They consist of a highly conserved
N-terminal domain, cathelin, and a variable C-terminal
peptide which is proteolytically released upon activation
(Zanetti et al., 1995; Sorensen et al., 2001). The single human
member of this family, 18 kDa human cationic antimicrobial
protein, hCAP18, is mainly produced by leukocytes and
epithelial and mucosal cells (Agerberth et al., 1995; Frohm
et al., 1997; Sorensen et al., 1997; Bals et al., 1998; Frohm
Nilsson et al., 1999; De et al., 2000). Its cationic C-terminal
37 amino-acid domain, LL-37 displays broad antimicrobial
activity (Dorschner et al., 2001; Zasloff, 2002) mediated
through direct interaction with and disruption of the
microbial cell membrane (Oren et al., 1999; Ramanathan
et al., 2002). In addition to being antimicrobial, LL-37 is
implicated in diverse biological processes, such as chemo-
taxis, cytokine production, histamine release, and angiogen-
esis (Koczulla et al., 2003; Braff et al., 2005; Shaykhiev et al.,
2005). Furthermore, human cathelicidin antimicrobial pep-
tide 18 kDa/LL-37 is highly expressed during normal wound
healing (Dorschner et al., 2001; Heilborn et al., 2005),
displays growth factor-like properties enhancing the in vitro
proliferation and migration of human keratinocytes, and is
involved in reepithelization of wounds (Heilborn et al., 2003,
2005). The signaling pathways induced by LL-37 are not fully
known, but current work identifies at least one receptor for
LL-37, the purinergic receptor P2X7 (Elssner et al., 2004).
Moreover, it was recently shown that LL-37 converts self-
DNA into a danger signal triggering autoimmunity in
psoriasis (Lande et al., 2007). At high concentrations,
exceeding 13 mM, LL-37 is cytotoxic to eukaryotic cells
(Johansson et al., 1998) by disrupting membrane integrity.
However, at low concentrations LL-37 has been shown to
modulate contrasting effects on apoptosis in different
mammalian cells types (Barlow et al., 2006; Lau et al.,
2006; Nagaoka et al., 2006). Suppression or induction of
apoptosis mediated by LL-37 seems to be dependent on
peptide concentration and/or cell type. The function of LL-37
in human keratinocyte apoptosis has not been studied.
Given the previously reported contrasting effects
on apoptosis mediated by LL-37, the present study was
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undertaken to investigate whether LL-37, in view of its
putative role in wound healing, would affect apoptosis
pathways in human keratinocytes. We report here that
treatment with LL-37 at a noncytotoxic concentration
protected keratinocytes from undergoing apoptosis and
regulated the expression of antiapoptotic genes such as
inhibitor of apoptosis protein-2 (IAP-2) and cyclooxygenase-2
(COX-2).
RESULTS
LL-37 suppresses camptothecin-induced apoptosis in
keratinocytes
To explore the hypothesis that LL-37 is involved in apoptosis
in primary normal human keratinocytes (NHKs), we exam-
ined the effect of LL-37 on cells exposed to camptothecin
(CAM). This drug is a topoisomerase I inhibitor and is broadly
used experimentally as an apoptosis-inducing agent (Pessina
et al., 2001). After treatment with CAM, membrane integrity
and DNA fragmentation were analyzed by flow cytometry
using two different methods. The first method differentiates
between apoptosis and necrosis measuring increased perme-
ability of the cell membrane to the dye YO-PRO as a marker
for apoptosis and propidium iodide staining (PI) as a marker
for necrosis. By the second method, the DNA content in
ethanol-permeabilized cells was analyzed by PI staining with
apoptotic cells showing less amount of DNA due to
fragmentation.
When exposed to 6 mM of CAM for 24 hours, HaCaT cells
as well as NHK displayed a staining pattern and a DNA
profile characteristic of apoptosis (Figure 1). NHK cells
pretreated with LL-37 showed a significant reduction in
the number of apoptotic cells compared with cells treated
with CAM alone (Figure 1a–e) (n¼3, Pp0.001). A similar
effect was seen for necrotic cells after pretreatment with
2 mM LL-37. Also in HaCaT cells LL-37 treatment signi-
ficantly (n¼ 2; Po0.05) reduced apoptosis induced by CAM
(Figure 2).
To validate these findings with a different method,
we performed DNA content analysis of NHK cells to
determine the extent of DNA fragmentation before and
after treatment with CAM, LL-37, or their combination
(Figure 3). In accordance with the previous findings,
the fraction of NHK cells with DNA fragmentation induced
by CAM, was significantly reduced (n¼ 3; Po0.01) by
pretreatment with 1 or 2 mM LL-37 (Figure 3). Although
treatment with CAM induced the number of cells with
a low DNA content (sub 2N) from 1.5% (Figure 3a) to 14.7%
(Figure 3d), pretreatment with 1 or 2mM LL-37 suppressed
it to 7.2% (Figure 3e) or 4.4% (Figure 3f), respectively,
demonstrating that LL-37 protects cells from CAM-induced
cell death (Figure 3). Interestingly, treatment of cell with 1 or
2 mM LL-37 alone also suppressed the fraction of sub-2N
cells from 1.5% (Figure 3a) to 0.9% (Figure 3b and c),
although this change was not statistically significant due
low number of sub-2N cells under normal cell culture
conditions.
Taken together, LL-37 is effective in protecting keratino-
cytes from CAM-induced cell death.
LL-37 inhibits caspase-3 activation in human primary
keratinocytes
As caspase-3 is one of the key proteins in the apoptosis
pathway and an early indicator of apoptosis, we measured
caspase-3 activity in keratinocytes upon treatment with CAM
and/or LL-37. We found that CAM significantly (n¼ 3;
Po0.01) induced caspase-3 activation 24 hours after treat-
ment (Figure 4). When NHK cells were pretreated with LL-37,
a significant (n¼3; Pp0.01) and concentration-dependent
decrease in CAM-induced activation of caspase-3 was found
(Figure 4) demonstrating that LL-37 inhibits caspase-3
activation in keratinocytes.
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Figure 1. LL-37 suppresses camptothecin-induced apoptosis in primary
keratinocytes. Apoptosis was induced in subconfluent keratinocyte cultures
by 6 mM CAM after pretreatment with 2 mM of LL-37 for 24 hours or medium
alone. Apoptosis was assessed by YO-PRO-1 and propidium iodide (PI)
staining after 24 hours of CAM treatment. Harvested cells were evaluated by
flow cytometry and categorized by quadrant analysis according to fluorescent
intensity as viable (no or little fluorescence), apoptotic (positive for YO-PRO-1
fluorescence) or necrotic (positive for both YO-PRO-1 and PI fluorescence).
One representative flow cytometry figure from one representative of three
independent experiments is shown. (a) Cells treated with medium alone. (b)
Cells treated with LL-37 alone. (c) Cells treated with CAM. (d) Cells treated
with LL-37 and CAM. (e) Box plot summarizing three independent
experiments each performed with triplicates. The following differences were
statistically significant: Control vs CAM (Pp0.001); CAM vs 2 mM
LL-37þCAM (Pp0.001); CAM vs 1mM LL-37þCAM (Pp0.001).
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LL-37 upregulates the expression of antiapoptotic genes in
keratinocytes
To gain a more complete understanding of how LL-37 affects
apoptosis in keratinocytes, we used gene array technology to
profile gene expression patterns in NHK cells 6 hours after
treatment with 2 mM LL-37. Analysis of data using the
‘‘Significance Analysis of Microarrays’’ algorithm identified
74 significantly differentially expressed genes (false discovery
rateo5%) between keratinocytes treated with LL-37 or
medium alone. The genome-wide portrait of LL-37-induced
changes in the gene expression profile of keratinocytes will
be presented elsewhere (C.I. Chamorro et al., unpublished
data). Among differentially expressed genes, we focused
specifically on those previously linked to apoptosis. We
found that LL-37 induced a twofold upregulation of the
prostaglandin endoperoxide synthetase gene (COX-2) in
keratinocytes, a gene important in the regulation of apoptosis
(Dempke et al., 2001; Cheuk et al., 2002; Slice et al., 2005;
Papadimitriou et al., 2007).
To validate the results obtained by the microarray analysis,
we next performed quantitative real-time PCR analysis of
COX-2 mRNA expression in LL-37-treated NHK cells (Figure
5a). In accordance with the results of the microarray,
treatment with 2 mM LL-37 induced a significant (n¼ 3;
Pp0.05), more than twofold increase in COX-2 mRNA levels
already after 6 hours, and sustained up to 24 hours (Figure 5a).
As the porcine homologue of LL-37 (PR-39) is known to
induce the expression of the IAP-2 (Wu et al., 2004) we also
set out to determine whether LL-37 was able to modulate the
expression of IAP-2 in keratinocytes by analyzing its
expression by reverse transcriptase–PCR. We found that
treatment of NHK cells with 2 mM LL-37 induced a significant
(n¼3; Pp0.05), almost twofold increase in IAP-2 mRNA
expression 6 and 12 but not 24 hours after LL-37 treatment
(Figure 5b). Thus, high expression of COX-2 at 24 hours does
not ensure a high IAP-2 mRNA level at later time points
(Figure 5b). It could be that this difference in mRNA levels
reflects different turnover of COX-2 and IAP-2 mRNAs in the
cell or alternatively that sustained activation of IAP-2 induces
a negative feedback loop. It is also important to note that
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Figure 2. LL-37 inhibits camptothecin-induced apoptosis in HaCat cells.
Subconfluent cells were pretreated for 24 hours with 2 mM of LL-37 or medium
alone. The cells were further cultured for 24 hours in absence or in presence
of 6mM CAM. The effect of LL-37 was evaluated by flow cytometry showing
the percentage of apoptotic (positive for YO-PRO-1 fluorescence) and
necrotic (positive for both YO-PRO-1 and PI fluorescence) cells after
treatment with CAM and/or LL-37. The figure shows mean±SD of one
representative experiment performed with triplicates. The experiment was
repeated three times. CAM vs 2 mM LL-37þCAM (Po0.01).
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Figure 3. LL-37 treatment suppresses DNA fragmentation in human primary
keratinocytes. Apoptosis was induced by 6 mM CAM in subconfluent primary
keratinocytes following pretreatment with 1 or 2 mM of LL-37 or medium alone
for 24 hours. DNA fragmentation was assessed by propidium iodide (PI)
staining after 24 hours of CAM treatment. One representative flow cytometry
histogram from one of two independent experiments showing DNA
fragmentation in cells treated with (a) medium alone, (b) 1 mM of LL-37, (c)
2mM of LL-37, (d) 6 mM CAM, (e) 6 mM CAM and 1 mM of LL-37, and (f ) 6 mM
CAM and 2 mM of LL-37. Cells were stained with PI and analyzed by flow
cytometry to detect nonapoptotic (2N to 4N) and apoptotic populations (sub
2N). (g) Box plot summarizing two independent experiments each performed
with triplicates.
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even though mRNA levels of IAP-2 go down, protein levels
may persist and thereby explaining the antiapoptotic effects.
These results demonstrate that LL-37 upregulates the expres-
sion of the antiapoptotic genes COX-2 and IAP-2 in NHKs.
LL-37 induces COX-2-dependent induction of PGE-2 in
keratinocytes
To determine whether the increased levels of COX-2
correlated with prostaglandin E-2 (PGE-2) production in
primary keratinocytes, we stimulated the cells with different
concentrations of LL-37 and measured the levels of PGE-2 in
cell culture supernatants at different time points (Figure 6).
We found that LL-37 induced a significant (n¼3; Po0.05),
time- and concentration-dependent increase of PGE-2 levels
in the culture media (Figure 6). Pretreatment of cells with a
selective COX-2 inhibitor, SC-791 (Tripp et al., 2003)
significantly (Pp0.05) decreased the levels of PGE-2 induced
by LL-37 indicating that the LL-37-induced PGE-2 production
was mediated by COX-2 (Figure 6). Together these results
indicate that LL-37 modulates both expression and activity of
COX-2 in keratinocytes.
Inhibition of COX-2 suppresses the antiapoptotic effects of
LL-37 in keratinocytes
Given the known antiapoptotic effects of prostaglandins we
tested whether the inhibition of COX-2 and therefore the
COX-2-dependent increase in PGE-2 production would affect
the antiapoptotic effect of LL-37 in keratinocytes. NHK cells
were pretreated for 30 minutes with 25 nM of the specific
COX-2 inhibitor, SC-791, and then treated with CAM, LL-37,
or both in combination. Apoptosis was assessed by measuring
caspase-3 activity (Figure 7). As anticipated, CAM treatment
induced a significant (n¼3; Po0.05) increase in caspase-3
activity, whereas pretreatment with LL-37 significantly (n¼ 3;
Po0.05) suppressed the CAM-induced caspase-3 activation
(Figure 7). Moreover, pretreatment of cells with the specific
COX-2 inhibitor suppressed the antiapoptotic effects of LL-
37. These results demonstrate that the antiapoptotic effects
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Figure 4. LL-37 inhibits activation of caspase-3 in human primary
keratinocytes. Apoptosis was induced in subconfluent keratinocyte cultures
by 6 mM CAM after 24 hours of pretreatment with 0.5, 1, or 2 mM of LL-37 or
medium alone. Caspase-3 activity was determined by the in vitro cleavage of
VDVAD-AMC. Data represent one of three different experiments each
performed with triplicates. Control vs CAM (Po0.0001); CAM vs 2 mM
LL-37þCAM (Po0.0001).
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Figure 5. LL-37 upregulates the expression of the antiapoptotic genes COX-2
and IAP-2 in human primary keratinocytes. Subconfluent keratinocyte
cultures were treated with 2 mM LL-37 (black columns) and harvested at 6, 12,
and 24 hours after stimulation. Cells treated with medium were used as
control (light grey columns). RNA from cells was reverse transcribed and the
relative expression of (a) COX-2 or (b) IAP-2 was determined for each time
point by RT–PCR. The results were normalized against 18S gene expression
and relative to the untreated cells (control set as 1 for each time point).
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Figure 6. LL-37 induces the release of PGE-2 in a COX-2-dependent manner
in human primary keratinocytes. Keratinocytes were treated with either 2 or
4mM of LL-37, medium, or in combination with the COX-2 inhibitor (SC-791).
Cells were pretreated with the specific COX-2 inhibitor SC-791 for
30 minutes, followed by incubation with 2 mM of LL-37 or medium alone for
6 hours. Supernatants were collected after 3, 6, 16, 24, and 48 hours and
assayed for PGE-2 levels by ELISA. Results from one representative
experiment performed with triplicates are shown.
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induced by LL-37 in keratinocytes are mediated — at least in
part — through COX-2.
IAP-2 induction by LL-37 is dependent on COX-2 activity
Different studies have suggested that PGE-2 can modulate the
expression of members of the inhibitor apoptosis proteins
family (IAPs) (Roy et al., 1997; Nishihara et al., 2003). To
determine whether the upregulation of IAP-2 by LL-37 was
mediated by COX-2 activity, we pretreated NHK cells with
the specific COX-2 inhibitor SC-791 before addition of LL-37
(Figure 8). 2 mM LL-37 induced a significant (n¼ 3; Po0.01),
almost twofold increase in IAP-2 mRNA expression in
comparison with medium-treated cells 6 hours after treatment
(Figure 8a). In contrast, pretreatment of keratinocytes with the
COX-2 inhibitor prevented LL-37-induced increase of IAP-2
mRNA (Po0.05) (Figure 8a). To investigate whether the
observed effects were dependent on PGE-2, the main product
of COX-2, we treated primary keratinocytes with PGE-2 and
analyzed IAP-2 expression (Figure 8b). Results of quantitative
real-time PCR analyses revealed a trend that treatment of
keratinocytes with PGE-2 upregulated the expression of IAP-2
(Figure 8b). These results suggest that the antiapoptotic effects
induced by LL-37 in keratinocytes are mediated — at least in
part — by COX-2 and IAP-2.
DISCUSSION
In the present study we investigated the function of the
antimicrobial peptide LL-37 in keratinocyte apoptosis. We
found that LL-37 protected human keratinocytes from CAM-
induced apoptosis. The antiapoptotic effect was associated
with a decrease in caspase-3 activity. Furthermore, we
showed that LL-37 upregulated the expressions of COX-2
and IAP-2, a member of the antiapoptotic family of proteins.
Moreover, LL-37 increased PGE-2 production in keratino-
cytes in a COX-2-dependent manner. In addition, we
demonstrated that inhibition of COX-2 suppressed both the
antiapoptotic effects of LL-37 and the expression of IAP-2.
These results suggest that the antiapoptotic effects induced by
LL-37 in keratinocytes are mediated — at least in part — by
COX-2 and IAP-2.
Contrasting effects on apoptosis have been described for
LL-37 (Barlow et al., 2006). At high concentrations (above
20 mM) LL-37 has cytotoxic effects on eukaryotic cells,
through mechanisms involving disruption of the cell mem-
brane, mitochondrial injury, and cytochrome c release
(Aarbiou et al., 2006) Moreover, high concentrations of LL-
37 induced apoptosis in epithelial carcinoma cell lines
(Okumura et al., 2004), and in air way epithelial cell lines
(Barlow et al., 2006; Lau et al., 2006). In contrast, here we
found that LL-37 peptide protected primary human keratino-
cytes and HaCaT cells from topoisomerase I inhibitor-
induced apoptosis. In agreement with our findings, anti-
apoptotic effects of LL-37 have been demonstrated in
neutrophils as a result of LL-37-mediated expression of
antiapoptotic proteins and decrease in caspase-3 activation
(Barlow et al., 2006; Nagaoka et al., 2006). Thus, the
contrasting effects of LL-37 on cell death may depend on
multiple factors including peptide concentration, the pre-
sence of serum components and most importantly the cell
type. Therefore, distinct apoptotic responses may occur due
to variations in signaling and processing of LL-37 in different
cells.
COX-2 is usually expressed at low or undetectable levels
in most cells, but is induced in response to proinflammatory
cytokines, growth factors, and tumor promoters (Dubois
et al., 1998). COX-2 produces PGE-2 that affects cell
proliferation (Shao et al., 2003; Krysan et al., 2005;
Papadimitriou et al., 2007) and decreases apoptosis in
different cell types (Liou et al., 2007; Papadimitriou et al.,
2007). COX-2 is frequently overexpressed in cancer and is
implicated in tumor progression (Chen et al., 2001; Dempke
et al., 2001; Barnes et al., 2006; Yalcin et al., 2007). We
found that LL-37 induces COX-2 expression and PGE-2
production in NHKs and that its antiapoptotic function is
partially mediated by this pathway. Moreover, we found that
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the upregulation of IAP-2 by LL-37 could be prevented by the
pretreatment of cells with COX-2 inhibitor. Furthermore,
PGE-2, the main product of COX-2 could also induce
IAP-2 expression. However, when we added all three
compounds (LL-37þCOX-2 inhibitorþPGE-2) together to
the cells there was no convincing rescue of the COX-2
inhibition. A possible explanation for this is that the
combined treatment had a negative effect on the cells. Still,
taken together, our data indicate that LL-37 upregulates IAP-2
by a COX-2-dependent mechanism. Interestingly, LL-37 is
overexpressed in several types of cancer and (Heilborn et al.,
2005; Coffelt et al., 2008; von Haussen et al., 2008) its
overexpression induces biological processes relevant for
tumor growth and progression including neoangiogenesis
(Koczulla et al., 2003), and increased cell proliferation and
migration (Heilborn et al., 2005; Coffelt et al., 2008; von
Haussen et al., 2008). Our data suggest that the induction of
COX-2 expression by LL-37 may play a role in cancer
development. The exact mechanism by which LL-37 induces
the expression of COX-2 is at present unknown and deserves
further investigation in the future.
LL-37 is emerging as a key player in skin biology being
implicated in wound healing (Heilborn et al., 2003;
Shaykhiev et al., 2005; Carretero et al., 2008) and is
overexpressed in psoriasis with a putative pathogenetic role
in disease manifestation (Lande et al., 2007). The tight
regulation of apoptosis in keratinocytes is critical for the
maintenance of normal epidermal turnover and for wound
healing. Experimental data suggest that inhibition of apopto-
sis in human keratinocytes accelerates reepithelialization and
wound closure (Xue et al., 2004).
Interestingly, LL-37 modulated the expression of IAP-2 by
a mechanism, which seems to be dependent of COX-2
activity. These results are in agreement with studies showing
that PGE-2 derived from COX-2 can modulate the expression
of members of the IAPs (Roy et al., 1997; Nishihara et al.,
2003). IAP-2 is widely recognized as a key regulator of
apoptosis and it operates through the direct inactivation of
caspase-3 (Roy et al., 1997). The porcine orthologue of LL-37
(PR-39) has also been shown to protect human cells from
apoptosis through the induction of IAP-2 expression suggest-
ing that the regulation of apoptosis by cathelicidins is
conserved through evolution (Wu et al., 2004; Ross et al.,
2007). These in vitro results could have in vivo relevance, as
both LL-37 and IAP-2 were recently reported to be over-
expressed in psoriatic skin (Tovar-Castillo et al., 2007). It was
suggested that LL-37 may be involved in the resistance to
apoptosis of dermal endothelial cells by the induction of IAP-
2 (Tovar-Castillo et al., 2007). We found in the present study
that LL-37 increased in vitro IAP-2 expression in human
keratinocytes; which may enhance keratinocyte survival and
resistance to apoptosis.
On the basis of our findings LL-37 protects human
keratinocytes from apoptosis by the activation of the COX-2
pathway. Therefore, LL-37 (or its receptor) may be a
promising therapeutic target for the treatment of diseases
characterized by high LL-37 expression and low apoptosis
such as cancer and psoriasis.
MATERIALS AND METHODS
Cell culture
Foreskin Epidermal keratinocytes (Cascade Biologics, Eugene, OR)
were cultured in Epilife basal medium (Cascade Biologics) supple-
mented with 60 mM calcium chloride, 0.2% (v/v) bovine pituitary
extracts (BPE), 5 mg ml1 bovine insulin, 0.18 mg ml1 hydrocorti-
sone, 5 mg ml1 bovine transferrin, 0.2 ng ml1 human epidermal
growth factor, 100 U ml1 penicillin G, 100mg ml1 streptomycin
sulfate, and 0.25mg ml1 Ampotericin B (all Cascade Biologics) at
37 1C and 5% CO2. Cells were passage weekly using 0.025% (w/v)
trypsin and 0.01% (w/v) EDTA.
HaCaT keratinocytes (a kind gift from R Fusenig) were cultured in
DMEM (Gibco-BRL Technology, Paisley, UK) supplemented with
10% fetal calf serum (HyClone, Boule Nordic AB, Huddinge,
Sweden), 2 mM glutamine, penicillin (50 U l1; Gibco-BRL), and
streptomycin (50 mg ml1; Gibco-BRL).
Drug treatment and apoptosis evaluation
Cell treatment. A total of 25,000 cells per well were plated in
six-well plates. At 48 hours after plating, cells were treated
with different concentrations of LL-37. Each treatment was
performed in triplicate. The peptide was diluted in medium (DMEM
with 5% fetal calf serum for HaCaT cells and Epilife basal medium
supplemented with 0.1% fetal calf serum for NHK cells). Cells were
treated for 24 hours, where after the topoisomerase I inhibitor CAM
(Sigma Chemical Co., St. Louis, MO) was added to a final
concentration of 6 mM. Cells were then incubated further for 24 hours
before analysis.
The specific COX-2 inhibitor SC-791 (Calbiochem, Darmstadt,
Germany) was used at 25 nM concentration in culture medium and
was applied to the cells at least 30 minutes before of LL-37 treatment.
Evaluation of apoptosis by flow cytometry
Two apoptotic parameters, loss of membrane integrity, and decrease
of DNA, were evaluated by flow cytometry.
Evaluation of membrane integrity. After stimulation with LL-37
and treatment with CAM, cells were harvested by trypsinization. The
cells were then washed in cold Dulbecco’s phosphate-buffered
saline and counted in a hemocytometer (Hausser Scientific,
Horsham, PA). Cell density was adjusted to 1 106 cells per ml in
phosphate-buffered saline. Apoptosis was evaluated by staining with
PI and YO-PRO dye (Molecular Probes, Eugene, OR). Stained cells
were analyzed on a FACScan (Becton Dickinson, San Jose, CA).
Cells were gated for analysis on the basis of the forward (FSC) and
side (SSC) light-scattering characteristics. Analysis of cells expressing
YO-PRO and PI was performed using Cell Quest software (Becton
Dickinson), which provided percentages of YO-PRO and PI-positive
cells. Cells that stained green with YO-PRO were considered
apoptotic (Idziorek et al., 1995). Cells that also stained red, with
PI, were necrotic. Live, viable cells take up little or no dye.
Analysis of DNA content by flow cytometry. The PI/RNase
staining buffer (Becton Dickinson) was used for this analysis.
Trypsinized cells were fixed in cold 70% (v/v) ethanol, and stored
until its use at 4 1C. The DNA content was measured through
incorporation of PI into DNA. Fluorometric analysis was performed
using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
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FSC and SSC of particles were simultaneously measured to
determine the size and the granularity of cells. The red fluorescence
of PI-stained nuclei was detected in the FL-4 window (600 nm band
pass filter and 35 nm band width). The intensity of fluorescence was
proportional to the cellular DNA content. Each histogram was
divided into two parts: (1) the area representing asynchronous,
nonapoptotic, live cells (cells in G1, S, and G2 phases with
DNA content equal to 2N to 4N); and (2) the area representing
apoptotic cells with a smaller quantity of DNA in comparison to
living cells.
Caspase-3 activity assay
Caspase-3 enzymatic activity was measured using the fluorometric
substrate DEVD-AMC (Ac-DEVD-AMC; Sigma-Aldrich, St Louis,
MO) (100mM) as previously described (Zhang et al., 2005). Briefly
cell lysates were combined in a reaction buffer (100 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 10% sucrose,
5 mM dithiothreitol, 1% NP-40, and 0.1% CHAPS (pH 7.25) and
added to a microtiter plate. The cleavage of the fluorogenic substrate
was monitored by AMC liberation in a Fluoroscan II plate reader
(Labsystems, Stockholm, Sweden). Fluorescence units were con-
verted to pmol of AMC using a standard curve generated from free
AMC. Data were analyzed by linear regression and are displayed as
caspase-3 activity (pmol AMC release per minute).
Quantitative real-time PCR
Total RNA was isolated from cells after different treatments
according to the manufacturer’s directions by using the Qiagen
RNasy kit (Operon Biotechnologies, Cologne, Germany). Reverse
transcription was performed with a first-strand synthesis kit
(Amersham Biosciences, St. Leon-Rot, Germany). The expression
of 18S, cIAP-2 and COX-2 was quantified using Quantitative real-
time PCR (DNA Engine Opticon 2 system; MJRsearch Incorporate).
The following primers were used: human 18S sense, 50-CGGCTACC
ACATCCAAGGAA-30; human 18S antisense, 50-GCTGGAATTACCG
CGGCT-30; human IAP-2 sense, 50-ATTTGATGAAAAGCGCCAA-30;
human IAP-2 antisense, 50-GCCACAACAGAAGCATTTGA-30; human
prostaglandin endoperoxide synthetase-2 (COX-2) sense, 50-TGAG
CATCTACGGTTTGCTG-30; human prostaglandin endoperoxide
synthetase-2 (COX-2) antisense, 50-TGCTTGTCTGGAACAACTGC-30.
Microarray
A microarray containing 14,000 human oligo 70 mers (Operon;
Qiagen), printed twice and produced at the SweGen DNA
Microarray Resource Center at Lund University was used to evaluate
the NHK response to LL-37. Total RNA was isolated as described
before. cDNA probes were prepared by reverse transcription from
20 mg of total RNA, labeled with the fluorescent cyanine dyes Cy3
and Cy5. The protocols employed for probe labeling, purification,
and hybridization were performed as described previously (Tollet-
Egnell et al., 2001). Analysis of the microarray results was performed
using the Significance Analysis of Microarrays tool (Stanford tools) as
described earlier (Tusher et al., 2001).
ELISA
Levels of PGE-2 in the culture supernatants of LL-37 treated and
untreated NHK during time periods were measured with a
commercially available ELISA using a PGE-2 High Sensitivity
Immunoassay kit (R&D Systems, Minneapolis, MN) Supernatants
were centrifuged to remove cell debris and were stored at –80 1C
until assayed. The results were expressed as pg PGE-2 per ml.
Statistical analysis
All experiments were performed in triplicate a minimum of three
times. Means and standard deviations were calculated. The signifi-
cance of the differences among the treatments was estimated by using
analysis of variance (ANOVA) and a Welsh two-sample t-test (Team,
2005). A P-value of 0.05 was considered statistically significant.
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